Haemonetics (HAE) Tops Q4 EPS by 2c, provides guidance
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 11/4/2026
- Wall Street rallies after Democrats win Congress; data center stocks slide
- What the Democratic sweep in the midterms means for markets
- SpaceX, Tesla slide as election risks mount, Morgan Stanley turns bullish
- CVS Health plans to split into two public companies by 2028
- AI sector outlook darkens as Democrat wins threaten $900B capex cycle
Tweet
Share
E-mailGet Alerts HAE Hot Sheet
Price: $126.49 +5.16%
EPS Growth %: +1.6%
Financial Fact:
Gross profit: 104.25M
Today's EPS Names:
ATS, SICP, FTCO, More
EPS Growth %: +1.6%
Financial Fact:
Gross profit: 104.25M
Today's EPS Names:
ATS, SICP, FTCO, More
Join SI Premium – FREE
Haemonetics (NYSE: HAE) reported Q4 EPS of $1.24, $0.02 better than the analyst estimate of $1.22. Revenue for the quarter came in at $331 million versus the consensus estimate of $330.66 million.
GUIDANCE:
Haemonetics sees FY2026 EPS of $4.70-$5.00, versus the consensus of $4.54.
For earnings history and earnings-related data on Haemonetics (HAE) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- MFA Financial (MFA) Misses Q3 EPS by 2c
- Scotts Miracle-Gro (SMG) Tops Q4 EPS by 5c ; Offers Guidance
- SelectQuote, Inc. (SLQT) Tops Q1 EPS by 13c ; Offers Guidance
Create E-mail Alert Related Categories
Earnings, GuidanceRelated Entities
Earnings, Maynard Um, Mark Zuckerberg, ARKSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
